A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts

David R Gandara, C. A. Ries, S. A. Schiff, C. B. George, J. P. Lewis, M. M. Koretz, S. K. Carter

Research output: Contribution to journalArticle

Abstract

Prednimustine, an ester of chlorambucil and prednisolone, was evaluated for efficacy and toxicity in a selected group of leukemia patients with a poor prognosis. Disease subsets consisted of patients with acute non-lymphocytic leukemia (ANLL) over age 60; ANLL refractory to standard therapy; smouldering leukemia; and refractory anemia with excess blasts (RAEB). In agreement with previous studies, toxicity from Prednimustine was relatively mild, consisting primarily of infrequent myelosuppression, gastrointestinal side-effects, and mild hyperglycemia. This study did not, however, confirm previously reported remission rates in ANLL: in 41 evaluable patients only two complete remissions were achieved. Both occurred in the subset of patients with smouldering leukemia. We conclude that Prednimustine has limited activity in this patient population.

Original languageEnglish (US)
Pages (from-to)10-12
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume9
Issue number1
DOIs
StatePublished - Sep 1982
Externally publishedYes

Fingerprint

Prednimustine
Refractory Anemia with Excess of Blasts
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Refractory materials
Toxicity
Chlorambucil
Prednisolone
Esters
Hyperglycemia
Leukemia
Population

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts. / Gandara, David R; Ries, C. A.; Schiff, S. A.; George, C. B.; Lewis, J. P.; Koretz, M. M.; Carter, S. K.

In: Cancer Chemotherapy and Pharmacology, Vol. 9, No. 1, 09.1982, p. 10-12.

Research output: Contribution to journalArticle

Gandara, David R ; Ries, C. A. ; Schiff, S. A. ; George, C. B. ; Lewis, J. P. ; Koretz, M. M. ; Carter, S. K. / A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts. In: Cancer Chemotherapy and Pharmacology. 1982 ; Vol. 9, No. 1. pp. 10-12.
@article{519fe4cd54554adc9a81c072de40e21c,
title = "A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts",
abstract = "Prednimustine, an ester of chlorambucil and prednisolone, was evaluated for efficacy and toxicity in a selected group of leukemia patients with a poor prognosis. Disease subsets consisted of patients with acute non-lymphocytic leukemia (ANLL) over age 60; ANLL refractory to standard therapy; smouldering leukemia; and refractory anemia with excess blasts (RAEB). In agreement with previous studies, toxicity from Prednimustine was relatively mild, consisting primarily of infrequent myelosuppression, gastrointestinal side-effects, and mild hyperglycemia. This study did not, however, confirm previously reported remission rates in ANLL: in 41 evaluable patients only two complete remissions were achieved. Both occurred in the subset of patients with smouldering leukemia. We conclude that Prednimustine has limited activity in this patient population.",
author = "Gandara, {David R} and Ries, {C. A.} and Schiff, {S. A.} and George, {C. B.} and Lewis, {J. P.} and Koretz, {M. M.} and Carter, {S. K.}",
year = "1982",
month = "9",
doi = "10.1007/BF00296753",
language = "English (US)",
volume = "9",
pages = "10--12",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts

AU - Gandara, David R

AU - Ries, C. A.

AU - Schiff, S. A.

AU - George, C. B.

AU - Lewis, J. P.

AU - Koretz, M. M.

AU - Carter, S. K.

PY - 1982/9

Y1 - 1982/9

N2 - Prednimustine, an ester of chlorambucil and prednisolone, was evaluated for efficacy and toxicity in a selected group of leukemia patients with a poor prognosis. Disease subsets consisted of patients with acute non-lymphocytic leukemia (ANLL) over age 60; ANLL refractory to standard therapy; smouldering leukemia; and refractory anemia with excess blasts (RAEB). In agreement with previous studies, toxicity from Prednimustine was relatively mild, consisting primarily of infrequent myelosuppression, gastrointestinal side-effects, and mild hyperglycemia. This study did not, however, confirm previously reported remission rates in ANLL: in 41 evaluable patients only two complete remissions were achieved. Both occurred in the subset of patients with smouldering leukemia. We conclude that Prednimustine has limited activity in this patient population.

AB - Prednimustine, an ester of chlorambucil and prednisolone, was evaluated for efficacy and toxicity in a selected group of leukemia patients with a poor prognosis. Disease subsets consisted of patients with acute non-lymphocytic leukemia (ANLL) over age 60; ANLL refractory to standard therapy; smouldering leukemia; and refractory anemia with excess blasts (RAEB). In agreement with previous studies, toxicity from Prednimustine was relatively mild, consisting primarily of infrequent myelosuppression, gastrointestinal side-effects, and mild hyperglycemia. This study did not, however, confirm previously reported remission rates in ANLL: in 41 evaluable patients only two complete remissions were achieved. Both occurred in the subset of patients with smouldering leukemia. We conclude that Prednimustine has limited activity in this patient population.

UR - http://www.scopus.com/inward/record.url?scp=0019980456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019980456&partnerID=8YFLogxK

U2 - 10.1007/BF00296753

DO - 10.1007/BF00296753

M3 - Article

C2 - 7139848

AN - SCOPUS:0019980456

VL - 9

SP - 10

EP - 12

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -